Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation

Xiaowei Chen, Sanford C. Garner, Leigh Quarles, John J.B. Anderson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

In this in vitro study, the hypothesis that the beneficial effects of dietary genistein on bone are through the modulation of the bone marker synthesis by osteoblastic MC3T3-E1 cells was tested, and the possible roles of estrogen receptors in the actions of genistein on osteoblastic cells were also examined. Interleukin-6 production was decreased 40% to 60% in osteoblastic cells treated with genistein from either day 8-16 or day 12-16, at dietarily achievable concentrations (10-10 to 10-8 M) (P<0.05). The mRNA expression of osteoprotegerin increased about 140% in cells treated from with genistein day 4-8 at a concentration of 10-8 M (P<0.05). The ratio of estrogen receptor-α to β expression increased 10-fold from day 0 to 12 of culture (P<0.05). Correlating with this time-dependent variation in estrogen receptor expression, treatments of 17β-estradiol and genistein had opposite dose patterns on the ratio of estrogen receptor-α to β expression following treatment from day 4 to 6 compared to from day 0 to 2. The addition of ICI-182,780, an estrogen receptor blocker, reduced the inhibitory effect of genistein on IL-6 production by 30-50%. In summary, these findings suggest that the beneficial skeletal effects of genistein, at dietarily achievable levels, appear to be mediated, at least in part, by interleukin-6 and osteoprotegerin, and estrogen receptors play important roles in the inhibition of interleukin-6 synthesis by genistein in osteoblastic MC3T3-E1 cells.

Original languageEnglish (US)
Pages (from-to)342-349
Number of pages8
JournalJournal of Nutritional Biochemistry
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Genistein
Cell Differentiation
Bone
Estrogen Receptors
Bone and Bones
Interleukin-6
Osteoprotegerin
Interleukin-6 Receptors
Estradiol
Modulation
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Nutrition and Dietetics
  • Clinical Biochemistry

Cite this

Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. / Chen, Xiaowei; Garner, Sanford C.; Quarles, Leigh; Anderson, John J.B.

In: Journal of Nutritional Biochemistry, Vol. 14, No. 6, 01.06.2003, p. 342-349.

Research output: Contribution to journalArticle

Chen, Xiaowei ; Garner, Sanford C. ; Quarles, Leigh ; Anderson, John J.B. / Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. In: Journal of Nutritional Biochemistry. 2003 ; Vol. 14, No. 6. pp. 342-349.
@article{fea5adc9359a4c65826867b5c9c421a3,
title = "Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation",
abstract = "In this in vitro study, the hypothesis that the beneficial effects of dietary genistein on bone are through the modulation of the bone marker synthesis by osteoblastic MC3T3-E1 cells was tested, and the possible roles of estrogen receptors in the actions of genistein on osteoblastic cells were also examined. Interleukin-6 production was decreased 40{\%} to 60{\%} in osteoblastic cells treated with genistein from either day 8-16 or day 12-16, at dietarily achievable concentrations (10-10 to 10-8 M) (P<0.05). The mRNA expression of osteoprotegerin increased about 140{\%} in cells treated from with genistein day 4-8 at a concentration of 10-8 M (P<0.05). The ratio of estrogen receptor-α to β expression increased 10-fold from day 0 to 12 of culture (P<0.05). Correlating with this time-dependent variation in estrogen receptor expression, treatments of 17β-estradiol and genistein had opposite dose patterns on the ratio of estrogen receptor-α to β expression following treatment from day 4 to 6 compared to from day 0 to 2. The addition of ICI-182,780, an estrogen receptor blocker, reduced the inhibitory effect of genistein on IL-6 production by 30-50{\%}. In summary, these findings suggest that the beneficial skeletal effects of genistein, at dietarily achievable levels, appear to be mediated, at least in part, by interleukin-6 and osteoprotegerin, and estrogen receptors play important roles in the inhibition of interleukin-6 synthesis by genistein in osteoblastic MC3T3-E1 cells.",
author = "Xiaowei Chen and Garner, {Sanford C.} and Leigh Quarles and Anderson, {John J.B.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0955-2863(03)00056-1",
language = "English (US)",
volume = "14",
pages = "342--349",
journal = "Journal of Nutritional Biochemistry",
issn = "0955-2863",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation

AU - Chen, Xiaowei

AU - Garner, Sanford C.

AU - Quarles, Leigh

AU - Anderson, John J.B.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - In this in vitro study, the hypothesis that the beneficial effects of dietary genistein on bone are through the modulation of the bone marker synthesis by osteoblastic MC3T3-E1 cells was tested, and the possible roles of estrogen receptors in the actions of genistein on osteoblastic cells were also examined. Interleukin-6 production was decreased 40% to 60% in osteoblastic cells treated with genistein from either day 8-16 or day 12-16, at dietarily achievable concentrations (10-10 to 10-8 M) (P<0.05). The mRNA expression of osteoprotegerin increased about 140% in cells treated from with genistein day 4-8 at a concentration of 10-8 M (P<0.05). The ratio of estrogen receptor-α to β expression increased 10-fold from day 0 to 12 of culture (P<0.05). Correlating with this time-dependent variation in estrogen receptor expression, treatments of 17β-estradiol and genistein had opposite dose patterns on the ratio of estrogen receptor-α to β expression following treatment from day 4 to 6 compared to from day 0 to 2. The addition of ICI-182,780, an estrogen receptor blocker, reduced the inhibitory effect of genistein on IL-6 production by 30-50%. In summary, these findings suggest that the beneficial skeletal effects of genistein, at dietarily achievable levels, appear to be mediated, at least in part, by interleukin-6 and osteoprotegerin, and estrogen receptors play important roles in the inhibition of interleukin-6 synthesis by genistein in osteoblastic MC3T3-E1 cells.

AB - In this in vitro study, the hypothesis that the beneficial effects of dietary genistein on bone are through the modulation of the bone marker synthesis by osteoblastic MC3T3-E1 cells was tested, and the possible roles of estrogen receptors in the actions of genistein on osteoblastic cells were also examined. Interleukin-6 production was decreased 40% to 60% in osteoblastic cells treated with genistein from either day 8-16 or day 12-16, at dietarily achievable concentrations (10-10 to 10-8 M) (P<0.05). The mRNA expression of osteoprotegerin increased about 140% in cells treated from with genistein day 4-8 at a concentration of 10-8 M (P<0.05). The ratio of estrogen receptor-α to β expression increased 10-fold from day 0 to 12 of culture (P<0.05). Correlating with this time-dependent variation in estrogen receptor expression, treatments of 17β-estradiol and genistein had opposite dose patterns on the ratio of estrogen receptor-α to β expression following treatment from day 4 to 6 compared to from day 0 to 2. The addition of ICI-182,780, an estrogen receptor blocker, reduced the inhibitory effect of genistein on IL-6 production by 30-50%. In summary, these findings suggest that the beneficial skeletal effects of genistein, at dietarily achievable levels, appear to be mediated, at least in part, by interleukin-6 and osteoprotegerin, and estrogen receptors play important roles in the inhibition of interleukin-6 synthesis by genistein in osteoblastic MC3T3-E1 cells.

UR - http://www.scopus.com/inward/record.url?scp=0037626862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037626862&partnerID=8YFLogxK

U2 - 10.1016/S0955-2863(03)00056-1

DO - 10.1016/S0955-2863(03)00056-1

M3 - Article

VL - 14

SP - 342

EP - 349

JO - Journal of Nutritional Biochemistry

JF - Journal of Nutritional Biochemistry

SN - 0955-2863

IS - 6

ER -